Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6000 participants.
Also called NCT06909565
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 6,000 participants
- Registry
-
NCT06909565
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06909565. Randomized; quadruple masking; primary purpose prevention. Start 2025-07-23 (actual); primary completion 2029-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
- Acronym
- V-INTERVENTION
- Condition
- Percutaneous Coronary Intervention
- Condition
- Peripheral Endovascular Intervention
- Intervention (Drug)
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Intervention (Drug)
- Normal Saline (Placebo)
- Lead sponsor
- Duke University
- Collaborator
- Novartis Pharmaceuticals
- Collaborator
- Colorado Prevention Center
- Collaborator
- Mount Sinai Hospital, New York
Record details
- Record id
cardio:ct-nct06909565- Content hash
ddfcb49ff8dc8d2c8cf0035d7e157ba93917a91078e76e1b15811bafffa4da60